This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
Here's Why You Should Retain Ensign Group (ENSG) Stock Now
by Zacks Equity Research
Ensign Group (ENSG) remains well-poised for growth on the back of solid segmental contributions, an expanding healthcare portfolio and sound cash reserves.
SYKNegative Net Change THCPositive Net Change HCAPositive Net Change ENSGPositive Net Change
medical
Avantor (AVTR) Launches Solutions for Gene Therapy Harvest
by Zacks Equity Research
Avantor's (AVTR) solutions are intended to provide gene therapy manufacturers with sustainable and efficient alternatives to traditional methods, thus improving viral particle harvest and quality
ECLPositive Net Change UHSPositive Net Change DVANegative Net Change AVTRNegative Net Change
medical medical-devices
Masimo's (MASI) WI Sport Wearable Gets a New Powerful Feature
by Zacks Equity Research
Masimo (MASI) announces Sleep Halo, a new feature for its Masimo W1 Sport advanced health tracking wearable.
ECLPositive Net Change UHSPositive Net Change DVANegative Net Change MASINegative Net Change
medical medical-devices
GE Healthcare (GEHC) Enters Partnership to Boost MRI Technology
by Zacks Equity Research
GE Healthcare's (GEHC) alliance is likely to establish an Innovative MRI Research and Development center to advance MRI innovation and patient care
ECLPositive Net Change UHSPositive Net Change DVANegative Net Change GEHCPositive Net Change
medical medical-devices
Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now
by Zacks Equity Research
PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.
ECLPositive Net Change UHSPositive Net Change DVANegative Net Change PACBPositive Net Change
medical medical-devices
Medtronic Loses 5% in a Month: What's Next for MDT Investors?
by Urmimala Biswas
Medtronic's (MDT) stock suffers as a result of geopolitical complications and supply issues despite an expanding portfolio and strong strategic executions.
ABTNo Net Change BSXPositive Net Change MDTPositive Net Change
medical
Elite Pharmaceuticals' (ELTP) FY24 Earnings Up, Gross Margin Down
by Zacks Equity Research
Elite Pharmaceuticals' (ELTP) overall top line benefits from revenue growth in Manufacturing fees.
ELTPNegative Net Change
earnings medical
Viking (VKTX) Skyrockets 197% YTD: Is the Stock Worth a Buy?
by Sundeep Ganoria
Despite having no marketed drugs, Viking's (VKTX) stock continues to experience robust price movement, driven by the company's encouraging progress with its pipeline.
NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change MDGLNegative Net Change
biotechs medical pharmaceuticals
4 Stocks That Boast Remarkable Interest Coverage Ratio
by Sumit Singh
A company capable of generating earnings well above its interest expense can withstand financial hardship. THC, LDOS, ATO and CBT are sound enough to meet financial obligations.
THCPositive Net Change ATOPositive Net Change CBTNegative Net Change LDOSPositive Net Change
aerospace basic-materials medical utilities
Neuronetics (STIM) Expands NeuroStar Portfolio With New Launch
by Zacks Equity Research
Neuronetics (STIM) announces the nationwide launch of the Better Me Provider (BMP) program developed in collaboration with TMS medical experts. The BMP program will be part of the company's NeuroStar product line.
JYNTPositive Net Change MEDPNegative Net Change STIMNo Net Change HIMSNegative Net Change
medical
Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag
by Zacks Equity Research
Longboard (LBPH) gains 14% as the FDA grants the Breakthrough Therapy designation to its investigational epilepsy treatment candidate, bexicaserin, for patients aged two years or older.
CGENNegative Net Change XENENegative Net Change ALXONegative Net Change LBPHNegative Net Change
biotechnology biotechs medical pharmaceuticals
Intuitive Surgical (ISRG) Rises 10% in a Month: What's Next?
by Indrajit Bandyopadhyay
Intuitive Surgical (ISRG) is making strides in the robotic-assisted surgery market with its existing and new launches. However, macro challenges are likely to continue to hurt its performance.
JNJNegative Net Change MDTPositive Net Change ISRGPositive Net Change
medical medical-devices
Mesoblast (MESO) Soars 208% YTD on Positive Regulatory Updates
by Zacks Equity Research
Mesoblast (MESO) skyrockets 208.2% year to date on encouraging progress with its pipeline candidates.
NVSNegative Net Change INCYNegative Net Change MESONegative Net Change ALXONegative Net Change
biotechnology biotechs cell-therapy medical pharmaceuticals
Is It the Right Time to Hold Labcorp (LH) in Your Portfolio?
by Zacks Equity Research
Labcorp's (LH) concentrated development in high-growth areas and strategic partnerships appear encouraging.
LHNegative Net Change RMDPositive Net Change MEDPNegative Net Change HIMSNegative Net Change
medical medical-devices
Tandem Diabetes (TNDM) Posts Positive Data for Tandem Mobi
by Zacks Equity Research
Tandem Diabetes (TNDM) unveils survey results of the new Tandem Mobi insulin delivery system, underscoring its potential to significantly enhance the quality of life for people with diabetes
DVANegative Net Change RMDPositive Net Change DXCMPositive Net Change TNDMNegative Net Change
medical medical-devices
CHMP Endorses Moderna's (MRNA) mRNA-based RSV Vaccine
by Zacks Equity Research
If approved, the RSV vaccine will be Moderna's (MRNA) second approved product in the European Union.
GSKNegative Net Change PFENegative Net Change MRNAPositive Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
FDA Rejects Rocket's (RCKT) Gene Therapy BLA for Rare Disease
by Zacks Equity Research
Per the FDA, Rocket (RCKT) needs to submit additional manufacturing information on Kresladi gene therapy to secure approval for severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder.
CGENNegative Net Change HRTXNegative Net Change RCKTNegative Net Change ARQTNegative Net Change
biotechs gene-therapy medical
PacBio (PACB) and Form Bio to Boost AAV Industry Development
by Zacks Equity Research
PacBio (PACB) and Form Bio collaborate to form an expert AAV Working Group to introduce essential tools for AAV development and research professionals.
ECLPositive Net Change UHSPositive Net Change DVANegative Net Change PACBPositive Net Change
medical medical-devices
Implied Volatility Surging for Fresenius Medical (FMS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Fresenius Medical (FMS) stock based on the movements in the options market lately.
FMSNegative Net Change
medical medical-devices
Merit Medical (MMSI) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Merit Medical's (MMSI) strong product portfolio.
ECLPositive Net Change DVANegative Net Change MMSIPositive Net Change LMATPositive Net Change
medical medical-devices
UnitedHealth (UNH), Amedisys Clear Merger Hurdle With Asset Sale
by Zacks Equity Research
By selling these assets, UnitedHealth (UNH) and Amedisys aim to avoid potential monopoly issues and ensure a smoother merger process.
UNHPositive Net Change AMEDPositive Net Change AURANegative Net Change ELVPositive Net Change
medical
Zacks.com featured highlights include Amkor Technology, Tenet Healthcare, Leidos and Maximus
by Zacks Equity Research
Amkor Technology, Tenet Healthcare, Leidos and Maximus are part of the Zacks Screen of the Week article.
THCPositive Net Change AMKRNegative Net Change MMSPositive Net Change LDOSPositive Net Change
aerospace business-services medical semiconductor
National Vision (EYE) Gains Market Share Despite Macro Woes
by Zacks Equity Research
National Vision (EYE) continues to execute core growth initiatives and further invest in strengthening competitive advantages.
JYNTPositive Net Change MEDPNegative Net Change EYENegative Net Change HIMSNegative Net Change
medical
Roche (RHHBY) Gets Positive CHMP Recommendation for Its Drugs
by Zacks Equity Research
Roche (RHHBY) gets CHMP recommendation for a label expansion of ophthalmology drug Vabysmo (faricimab) and PiaSky (crovalimab) for the treatment of paroxysmal nocturnal haemoglobinuria.
REGNNegative Net Change RHHBYNegative Net Change NERVNegative Net Change ALXONegative Net Change
biotechnology medical pharmaceuticals
Zacks Value Trader Highlights: BASF, Ford Motor, KB Home, PVH and Universal Health Services
by Zacks Equity Research
BASF, Ford Motor, KB Home, PVH and Universal Health Services are part of the Zacks Value Trader blog.
FPositive Net Change UHSPositive Net Change BASFYPositive Net Change KBHNegative Net Change PVHNegative Net Change
auto-tires-trucks construction consumer-discretionary industrial-products medical